Lay­ing claim to an­oth­er AI 'first,' Ex­sci­en­tia tees up an I/O drug for the clin­ic

In Jan­u­ary 2020, Ex­sci­en­tia an­nounced that a drug mol­e­cule to treat OCD in­vent­ed by AI was set to en­ter clin­i­cal tri­als for the first time. A lit­tle over a year lat­er, its AI-de­signed mol­e­cule for im­muno-on­col­o­gy will do the same.

The A2a re­cep­tor an­tag­o­nist was co-de­vel­oped with Evotec and has the po­ten­tial to pre­vent adeno­sine from bind­ing to T-cell re­cep­tors, pro­mot­ing an­ti-tu­mor T-cell ac­tiv­i­ty. Ex­sci­en­tia CEO An­drew Hop­kins said in a state­ment that the mol­e­cule was dis­cov­ered with­in 8 months from project ini­ti­a­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER